tranScrip Welcomes Markas Marriott as Senior Director of Regulatory Affairs

tranScrip is delighted to announce the appointment of Markas Marriott as Senior Director of Regulatory Affairs, completing the Regulatory Affairs Senior Leadership Team alongside Michelle Gafa and Roz Sutton.

Markas joins tranScrip at a pivotal moment, bringing over 30 years of regulatory expertise across the Pharmaceutical, Biotech, Healthcare, and Consulting industries. His addition to the team reinforces tranScrip’s commitment to strengthening and expanding our Regulatory Affairs services as we head into 2025. 

Markas comes to tranScrip directly from GSK, where he served as a Global Regulatory Lead, driving regulatory strategies for multiple clinical development assets in infectious diseases and respiratory conditions. His contributions included pioneering the use of AI to accelerate submission timelines, designing complex platform trials, and advancing early paediatric development. 

His consulting background is equally impressive. Prior to GSK, Markas spent 10 years in a senior role at ICON, where he contributed to business development and regulatory service expansion. His career has also included leadership roles at SFL, PWC, Shire, Baxter, Knoll, Boots, and SmithKline Beecham. 

Markas’ regulatory expertise spans ATMPs, Cell & Gene Therapy, devices, combination products, and small and large molecules. His experience covers pre- and post-approval strategies across various therapeutic areas, including CTAs/INDs, FDA meetings, scientific advice, Orphan Drug designation, NDAs, MAAs, PiPs/iPsPs, and due diligence. 

In addition to his vast regulatory background, Markas holds an impressive academic portfolio, including an MBA, a Law Degree, and a Biological & Biochemical Sciences degree (with a Regulatory Affairs focus). He is also a qualified solicitor. 

Karen Nugent, Chief Operating Officer at tranScrip, commented: “We are delighted to welcome Markas to tranScrip. His exceptional regulatory expertise, strategic mindset, and leadership experience make him a key addition to our growing Regulatory Affairs team. Markas’ appointment reflects our commitment to delivering innovative solutions and best-in-class support to our clients as we continue to expand in 2025.”  

Speaking on his appointment, Markas said: “I’m thrilled to join the talented team at tranScrip and contribute to the growth of our Regulatory Affairs services. I look forward to collaborating with the team, driving new opportunities, and helping our clients successfully navigate complex regulatory pathways to bring medicines to patients swiftly.” 

As a key member of tranScrip’s leadership, Markas will play a critical role in driving our delivery of excellent Regulatory Affairs consultancy for our clients within tranScrip.